[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:follicular-helper-t-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":31,"states":32},"Follicular Helper T-Cell Lymphoma",3,2,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07293403","Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas",[12],"Phase 2","RECRUITING","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.284314Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06561048","Soquelitinib vs Standard of Care in Participants With Relapsed\u002FRefractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",[20],"Phase 3","2026-08-26T02:15:26.669629Z","2026-05-05T02:43:28.359184Z",{"nct_id":24,"title":25,"phases":26,"status":28,"updated_at":29,"content_modified":30},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[27],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",[],[33],{"state":34,"count":5,"slug":35},"California","california"]